Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study

AIMS: Mesalamine is the first‐line therapy for treating mild‐to‐moderate ulcerative colitis. Multiple mesalamine formulations are available, with similar safety and efficacy profiles. Mesalamine is commonly administered as divided dosing, although once‐daily dosing may provide benefits for patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Vande Casteele, Niels, Jakate, Abhijeet, McNamee, Brian, Sandborn, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328660/
https://www.ncbi.nlm.nih.gov/pubmed/32671846
http://dx.doi.org/10.1111/bcp.14479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328660/
https://www.ncbi.nlm.nih.gov/pubmed/32671846
http://dx.doi.org/10.1111/bcp.14479

Ejemplares similares